@article{mbs:/content/journal/jgv/10.1099/jgv.0.000889, author = "Gurtsevitch, V. E. and Senyuta, N. B. and Ignatova, A. V. and Lomaya, M. V. and Kondratova, V. N. and Pavlovskaya, A. I. and Dushenkina, T. E. and Maximovich, D. M. and Smirnova, K. V. and Mudunov, A. M. and Lichtenstein, A. V.", title = "Epstein–Barr virus biomarkers for nasopharyngeal carcinoma in non-endemic regions", journal= "Journal of General Virology", year = "2017", volume = "98", number = "8", pages = "2118-2127", doi = "https://doi.org/10.1099/jgv.0.000889", url = "https://www.microbiologyresearch.org/content/journal/jgv/10.1099/jgv.0.000889", publisher = "Microbiology Society", issn = "1465-2099", type = "Journal Article", keywords = "NPC", keywords = "EBV serology", keywords = "plasma DNA EBV", abstract = "The Epstein–Barr virus (EBV) plays a key role in the development of undifferentiated nasopharyngeal carcinoma (uNPC). In uNPC endemic regions EBV-specific antibodies and plasma EBV DNA load are used as markers for the early detection of uNPC and monitoring of the disease. In non-endemic regions, such studies were practically not conducted. The aim of this study was to compare the clinical significance of EBV serological markers and plasma EBV DNA levels for uNPC patients in a non-endemic region, Russia. The results obtained indicate that both viral capsid antigen/immunoglobulin A (VCA/IgA) antibodies and plasma EBV DNA copies can effectively be used for nasopharyngeal carcinoma (NPC) diagnosis. Besides, plasma EBV DNA load was found to be a more sensitive marker of uNPC than VCA/IgA antibody titres, as it reflected the effect of the therapy in stages of remission and relapse of the disease more precisely. Our study, for the first time, demonstrates that the simultaneous use of plasma EBV DNA loads and VCA/IgA antibody levels are indispensable markers for uNPC in non-endemic regions: a serological marker can be more effectively used for NPC screening, but EBV DNA copies are better for monitoring the disease. However, both markers turned out to be practically unsuitable for assessing the clinical status of patients. Serological markers did not correlate with any signs of the tumour process estimated by tumour, node and metastasis (TNM) classification and the plasma EBV DNA loads correlated only with the size of the pathologically altered lymph nodes (N). Additional study is required to confirm these findings.", }